Rhinomed Limited (RHNMF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rhinomed Limited (RHNMF) trades at $0.019. Rhinomed Limited is an Australian healthcare company focused on developing and commercializing wearable nasal technology. Market cap: $5.45M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for RHNMF: RHNMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RHNMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RHNMF.
How is this calculated? →Rhinomed Limited (RHNMF) Healthcare & Pipeline Overview
Rhinomed Limited, an Australian medical device company, develops and commercializes wearable nasal technology for improved breathing, sleep, and diagnostics. Their product portfolio includes devices like Turbine, Mute, Pronto, and Rhinoswab, targeting consumer and medical markets. The company operates globally, focusing on respiratory health and drug delivery platforms.
What Is the Investment Thesis for RHNMF?
Rhinomed Limited presents a speculative investment opportunity within the medical device sector. The company's focus on wearable nasal technology and its diverse product portfolio targeting breathing, sleep, and diagnostics offers potential for growth. However, the company's negative profit margin of -146.0% and gross margin of -2.5% indicate significant challenges in achieving profitability. Key value drivers include successful commercialization of existing products like Turbine, Mute, Pronto, and Rhinoswab, as well as the development and launch of new programs in areas such as sleep apnea and drug delivery. Upcoming catalysts include potential partnerships, regulatory approvals, and expansion into new geographic markets. Potential risks include competition from established medical device companies, challenges in achieving market adoption of its products, and the need for additional funding to support ongoing operations and research and development.
Based on FMP financials and quantitative analysis
RHNMF Key Highlights
Market capitalization of $5.45M, indicating a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -1.05, reflecting the company's current lack of profitability.
- Profit margin of -146.0%, highlighting significant challenges in achieving profitability.
- Gross margin of -2.5%, indicating that the cost of goods sold exceeds revenue.
- Beta of 0.88, suggesting that the stock is less volatile than the overall market.
Who Are RHNMF's Competitors?
RHNMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| DOCRF CloudMD Software & Services Inc. | $0.02 | -19.29% | $6.25M | 38 |
| DTXMF Deltex Medical Group plc | $0.10 | +0.00% | $181M | 51 |
| FFLWF Fire & Flower Holdings Corp. | $0.12 | -44.37% | $5.42M | 41 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RHNMF's Key Strengths?
Innovative wearable nasal technology.
- Diverse product portfolio targeting multiple markets.
- Established distribution network.
- Ongoing research and development efforts.
What Are RHNMF's Weaknesses?
Negative profit margin and gross margin.
- Limited financial resources.
- Dependence on key products for revenue.
- Small market capitalization.
What Could Drive RHNMF Stock Higher?
Potential regulatory approvals for new diagnostic applications of Rhinoswab.
- Strategic partnerships with pharmaceutical companies for drug delivery platforms.
- Expansion into new geographic markets, including North America and Europe.
- Clinical trials and validation of Mute's efficacy in treating sleep apnea.
- Development of new products and technologies in the respiratory health market.
What Are the Key Risks for RHNMF?
Financial-distress signal — its Altman Z-Score of -9.51 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies.
- Regulatory hurdles and delays in obtaining approvals.
- Challenges in achieving market adoption of new products.
- Dependence on key products for revenue.
- Need for additional funding to support operations and research.
What Are the Growth Opportunities for RHNMF?
- Expansion into the sleep apnea market: The market for sleep apnea devices is projected to reach $12.1 billion by 2027. Rhinomed's Mute device and its ongoing research into sleep architecture and respiratory function provide an opportunity to capture a share of this growing market. Success hinges on clinical validation of Mute's efficacy and strategic partnerships with sleep clinics and healthcare providers.
- Development of drug delivery platforms: Rhinomed's drug delivery platform for cannabinoid formulations presents a significant growth opportunity in the pharmaceutical sector. The global cannabinoid market is expected to reach $47.2 billion by 2028. Rhinomed can leverage its nasal technology to deliver cannabinoid-based therapies for pain management, nausea relief, and other indications, pending regulatory approvals and clinical trials.
- Geographic expansion: Rhinomed currently operates worldwide, but further expansion into key markets such as North America and Europe could drive revenue growth. This includes establishing distribution partnerships, obtaining regulatory approvals, and tailoring its products to meet the specific needs of each market. The timeline for this expansion depends on securing funding and navigating regulatory hurdles.
- Strategic partnerships and collaborations: Collaborating with established medical device companies or pharmaceutical firms could accelerate Rhinomed's growth. These partnerships could provide access to new markets, technologies, and funding. Potential areas for collaboration include joint product development, licensing agreements, and distribution partnerships. The success of these partnerships depends on identifying suitable partners and negotiating mutually beneficial agreements.
- Expanding diagnostic capabilities with Rhinoswab: Rhinomed's Rhinoswab product offers a growth opportunity in the diagnostics market. By expanding the applications of Rhinoswab to detect various respiratory pathogens and diseases, Rhinomed can tap into the growing demand for rapid and accurate diagnostic tools. This includes securing regulatory approvals for new diagnostic applications and establishing partnerships with diagnostic laboratories and healthcare providers.
What Are RHNMF's Competitive Advantages?
- Proprietary nasal technology and patents.
- Established brand recognition in the wearable nasal device market.
- Distribution network through online and retail channels.
- Ongoing research and development efforts to innovate new products.
- First-mover advantage in specific niche markets.
What Does RHNMF Do?
Rhinomed Limited, originally founded as Consegna Group Limited in 2004 and rebranded in November 2013, is an Australian healthcare company headquartered in Cremorne. The company specializes in the research, development, and commercialization of innovative consumer and medical devices centered around nasal and respiratory technology. Rhinomed's core focus is on creating wearable nasal solutions that enhance breathing, improve sleep quality, and aid in the diagnosis of diseases. Their flagship products include Turbine, designed to improve airflow during sports; Mute, which reduces snoring by promoting nasal breathing; Pronto, a vapor inhaler for enhanced airflow and sleep; and Rhinoswab, a nasal swab collection device. Beyond its existing product line, Rhinomed is actively engaged in developing programs across various healthcare segments, including sleep architecture, the impact of respiratory function on cognitive issues, obstructive sleep apnea, pain management, nausea relief, respiratory disease treatment, and advanced diagnostics and sensors. The company also offers a drug delivery platform for cannabinoid formulations, expanding its reach within the pharmaceutical sector. Rhinomed distributes its products worldwide, targeting both consumer and medical markets with its innovative nasal technologies.
What Products and Services Does RHNMF Offer?
- Researches and develops wearable nasal technology.
- Commercializes consumer and medical devices globally.
- Offers Turbine for enhanced breathing during sports.
- Provides Mute to reduce snoring and improve nasal breathing.
- Markets Pronto, a vapor inhaler for improved airflow and sleep.
- Sells Rhinoswab for collecting nasal samples.
- Develops drug delivery platforms for cannabinoid formulations.
- Engages in research programs related to sleep, respiratory function, and diagnostics.
How Does RHNMF Make Money?
- Develops and manufactures wearable nasal devices.
- Sells products directly to consumers through online channels.
- Distributes products through retail partners and healthcare providers.
- Generates revenue through product sales and licensing agreements.
- Pursues research and development grants to fund innovation.
What Industry Does RHNMF Operate In?
Rhinomed Limited operates in the medical device industry, which is characterized by continuous innovation and technological advancements. The market is highly competitive, with established players like BLMHF (Bellerophon Therapeutics), CHNC (Chance Pharmaceuticals) and DOCRF (Second Sight Medical Products) as well as smaller companies vying for market share. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for minimally invasive procedures. Rhinomed's focus on wearable nasal technology positions it within the respiratory and sleep therapy segments, which are experiencing growth due to increasing awareness of sleep disorders and respiratory conditions.
Who Are RHNMF's Key Customers?
- Athletes seeking to improve breathing during exercise.
- Individuals suffering from snoring and sleep disturbances.
- Patients requiring nasal swab collection for diagnostic testing.
- Healthcare providers using nasal devices for respiratory therapy.
- Pharmaceutical companies seeking drug delivery platforms.
Key Financial Metrics
Its free cash flow yield is -63.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.27 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -95.5%, the inverse of the P/E and a quick read on earnings relative to price.
Rhinomed Limited (RHNMF) Valuation Context
Valued at $5.45M, RHNMF is classified as a micro-cap stock.
Company Profile
Rhinomed Limited operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Cremorne, AU. The company is led by CEO Michael Johnson. RHNMF has traded publicly since 2017.
Financial Health
Rhinomed Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.51 places it in the distress zone, a signal of elevated financial risk.
RHNMF Financials
Bull Case vs Bear Case
Bull Case
- Innovative wearable nasal technology.
- Diverse product portfolio targeting multiple markets.
- Established distribution network.
- Ongoing research and development efforts.
Bear Case
- Negative profit margin and gross margin.
- Limited financial resources.
- Dependence on key products for revenue.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RHNMF Latest News
No recent news available for RHNMF.
RHNMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RHNMF.
Price Targets
Wall Street price target analysis for RHNMF.
RHNMF MoonshotScore
What does this score mean?
The MoonshotScore rates RHNMF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael Johnson
CEO
Michael Johnson serves as the CEO of Rhinomed Limited, bringing extensive experience in the healthcare and medical device industries. His background includes leadership roles in various companies focused on commercializing innovative medical technologies. Johnson's expertise spans strategic planning, product development, and market expansion. He has a proven track record of driving growth and building successful teams in the healthcare sector. His educational background includes advanced degrees in business and engineering, providing a strong foundation for leading a technology-driven company like Rhinomed.
Track Record: Under Michael Johnson's leadership, Rhinomed Limited has focused on expanding its product portfolio and market reach. Key achievements include the commercialization of new nasal devices, strategic partnerships to enhance distribution, and ongoing research and development efforts to innovate new technologies. Johnson has also overseen the company's efforts to secure regulatory approvals and expand into new geographic markets. His strategic decisions have positioned Rhinomed as a key player in the wearable nasal technology market.
RHNMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rhinomed Limited may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports to the public. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for lower trading volume and liquidity.
- Increased price volatility due to limited trading activity.
- Higher risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings.
- Established history of operations since 2004.
- Focus on research, development, and commercialization of medical devices.
- Presence in the wearable nasal technology market.
- Global distribution network.
- Patents and proprietary technology.
What Investors Ask About Rhinomed Limited (RHNMF) — Healthcare
What does Rhinomed Limited do?
Rhinomed Limited is an Australian healthcare company specializing in the development and commercialization of wearable nasal technology. The company's core business revolves around creating and marketing innovative nasal devices designed to improve breathing, enhance sleep quality, and aid in disease diagnostics. Their product portfolio includes Turbine, Mute, Pronto, and Rhinoswab, targeting both consumer and medical markets. Rhinomed operates globally, focusing on respiratory health and drug delivery platforms.
What do analysts say about RHNMF stock?
Analyst coverage of RHNMF is limited due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-1.05) and profit margin (-146.0%) reflect the company's current lack of profitability. Growth considerations include the successful commercialization of existing products, expansion into new markets, and development of new technologies.
What are the main risks for RHNMF?
The main risks for Rhinomed Limited include competition from established medical device companies, regulatory hurdles and delays in obtaining approvals, challenges in achieving market adoption of new products, dependence on key products for revenue, and the need for additional funding to support operations and research. The company's negative profit margin and gross margin also pose significant financial risks.
What are the key factors to evaluate for RHNMF?
Evaluate RHNMF on fundamentals, analyst consensus, and risk factors. Rhinomed Limited presents a speculative investment opportunity within the medical device sector. Not financial advice.
How frequently does RHNMF data refresh on this page?
RHNMF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RHNMF's recent stock price performance?
Rhinomed Limited (RHNMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative wearable nasal technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RHNMF overvalued or undervalued right now?
Rhinomed Limited (RHNMF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RHNMF before investing?
Before investing in Rhinomed Limited (RHNMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for RHNMF.
- Financial data based on available public information.
- OTC market investments carry higher risks.